Drugs that contain Niraparib Tosylate

1. List of Zejula drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436185 GLAXOSMITHKLINE Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(6 years from now)

US8071623 GLAXOSMITHKLINE Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 GLAXOSMITHKLINE DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(4 years from now)

US8143241 GLAXOSMITHKLINE DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(4 years from now)

US8859562 GLAXOSMITHKLINE Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(8 years from now)

US11091459 GLAXOSMITHKLINE Niraparib compositions
Mar, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 29, 2027
New Chemical Entity Exclusivity (NCE) Mar 27, 2022
New Indication (I) Apr 29, 2023

NCE-1 date: March, 2021

Market Authorisation Date: 27 March, 2017

Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in